Moreover, Regulation (EU) 2019/6 provides for the procedure to designate certain antimicrobials to be reserved for the treatment of infections in humans. Such antimicrobials are not to be used in antimicrobial medicinal products administered to animals. That measure aims to preserve the efficacy of certain antimicrobials used to treat infections in humans, especially those considered treatments of last resort. Criteria for the designation of antimicrobials reserved for the treatment of certain infections in humans are laid down in Commission Delegated Regulation (EU) 2021/1760 [Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans (OJ L 353, 6.10.2021, p. 1).] and the list of antimicrobials reserved for treatment of certain infections in humans is set out in Commission Implementing Regulation (EU) 2022/1255 [Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022 designating antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans, in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council (OJ L 191, 20.7.2022, p. 58).].
Recital 3, Regulation (EU) 2023/905
In forcesince 27 Feb 2023